National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

bromocriptine mesylate
The mesylate salt of bromocriptine, a semisynthetic ergot alkaloid with dopaminergic, antidyskinetic, and antiprolactinemic activities. Bromocriptine selectively binds to and activates postsynaptic dopamine D2 receptors in the corpus striatum of the central nervous system (CNS). Activation of these D2 receptors activate inhibitory G-proteins, which inhibit adenylyl cyclase, preventing signal transduction mediated via cAMP and resulting in the inhibition of neurotransmission and an antidyskinetic effect. Ths agent also stimulates dopamine D2 receptors in the anterior pituitary gland, which results in the inhibition of prolactin secretion and lactation and may inhibit the proliferation of prolactin-dependent breast cancer cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Parlodel
Abbreviation:BRCR
Chemical structure name:ergotaman-3´,6´,18-trione, 2-bromo-12´-hydroxy-2´-(1-methylethyl)-5´-(2-methylpropyl)-, (5´a)-mono-methanesulfonate



Previous:brequinar, brivanib alaninate, broad-spectrum human papillomavirus vaccine V505, broccoli sprout extract, bromelain
Next:bromodeoxyuridine, bromovinyl-deoxyuridine, brostallicin, bruceantin, bryostatin 1

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov